MedTrace Logo

SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry

NCT00844285 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3072

Last updated 2023-05-06

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to monitor safety outcomes of patients who have taken Cimzia® as compared to a non- Cimzia® control population. The SECURE Registry's target enrollment is 3045 patients and it's objective is to monitor patients for approximately 8 years.

Conditions

Interventions

DRUG

Cimzia

The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.

Sponsors & Collaborators

  • UCB BIOSCIENCES, Inc.

    lead INDUSTRY

Principal Investigators

  • UCB Cares · 001 844 599 2273(UCB)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-30
Primary Completion
2020-08-21
Completion
2020-08-21
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00844285 on ClinicalTrials.gov